<div style="max-width: 900px; margin: 0 auto; font-family: 'Segoe UI',sans-serif; color: #2d3748; background: #fff; border-radius: 20px; box-shadow: 0 25px 50px -12px rgba(0,0,0,0.25); overflow: hidden;"> <div style="background: linear-gradient(135deg,#1e3c72,#2a5298); color: white; padding: 30px; text-align: center;"> <h1 style="margin: 0; font-size: 2.2em;">Microvascular Dysfunction in Atherosclerotic Coronary Disease</h1> <p style="margin: 10px 0 0; font-size: 1.1em; opacity: 0.9;">Clinical Reference Card for Master in Internal Medicine Exam Preparation</p> </div> <div style="padding: 30px;"> <p><!– EXECUTIVE SUMMARY –></p> <h2>🎯 EXECUTIVE SUMMARY</h2> <p>Coronary microvascular dysfunction (CMD) is a prevalent yet underdiagnosed condition in patients with atherosclerotic coronary artery disease (CAD). It independently predicts adverse cardiovascular outcomes, including myocardial infarction, heart failure, and death. CMD involves functional and structural abnormalities of the coronary microcirculation (vessels <500 μm) that impair myocardial perfusion despite the absence of significant epicardial stenosis. In patients with non-obstructive CAD, CMD is present in up to 50–65% of cases and is linked to poor prognosis. (Ong et al., <em>J Am Coll Cardiol</em>, 2020; Kaski et al., <em>Eur Heart J</em>, 2018). The condition is associated with traditional risk factors (hypertension, diabetes, smoking) and systemic inflammatory states. Diagnosis requires invasive coronary function testing or non-invasive imaging (e.g., PET, CMR). Treatment focuses on risk factor modification, anti-ischemic therapy, and emerging agents targeting microvascular function. (Ford et al., <em>Circulation</em>, 2020; Camici & Crea, <em>N Engl J Med</em>, 2007).</p> <p><!– STUDY OVERVIEW –></p> <h2>🔬 STUDY OVERVIEW</h2> <p>This reference card synthesizes key evidence from major clinical trials and consensus statements on CMD in the context of atherosclerotic coronary disease. The landmark studies include:</p> <ul> <li><strong>CorMicA Trial</strong> (Ford et al., <em>J Am Coll Cardiol</em>, 2018): Randomized controlled trial demonstrating that invasive coronary function testing improves angina control and quality of life in patients with suspected CMD.</li> <li><strong>WISE Study</strong> (Merz et al., <em>Circulation</em>, 2006): Prospective cohort showing that CMD is highly prevalent in women with chest pain and non-obstructive CAD, predicting major adverse events.</li> <li><strong>PET Prognosis Studies</strong> (Murthy et al., <em>Circulation</em>, 2011; Taqueti et al., <em>J Am Coll Cardiol</em>, 2015): Demonstrated that impaired coronary flow reserve (CFR) measured by PET independently predicts mortality and heart failure hospitalization.</li> <li><strong>Consensus Statements</strong> (Ong et al., <em>Eur Heart J</em>, 2020; Knuuti et al., <em>Eur Heart J</em>, 2020): Provide diagnostic criteria and treatment algorithms for CMD.</li> </ul> <p><!– KEY RESULTS –></p> <h2>📊 KEY RESULTS</h2> <div style="background: #f8fafc; border-radius: 12px; padding: 20px; margin: 15px 0;"> <h3>Prevalence and Prognosis</h3> <ul> <li>CMD present in 50–65% of patients with non-obstructive CAD (Ong et al., <em>J Am Coll Cardiol</em>, 2020).</li> <li>Impaired CFR (≤2.0) associated with 3- to 4-fold increased risk of MACE (Taqueti et al., <em>J Am Coll Cardiol</em>, 2015).</li> <li>In WISE study, CMD predicted 5-year MACE rate of 16% vs. 7% in controls (Merz et al., <em>Circulation</em>, 2006).</li> </ul> <h3>Diagnostic Performance</h3> <ul> <li>Invasive coronary function testing (CFR, IMR) has sensitivity 85–90% for CMD (Ford et al., <em>J Am Coll Cardiol</em>, 2018).</li> <li>PET CFR <2.0 has 80% sensitivity and 85% specificity for predicting adverse outcomes (Murthy et al., <em>Circulation</em>, 2011).</li> <li>CMR myocardial perfusion reserve index <1.5 correlates with invasive measures (Liu et al., <em>JACC Cardiovasc Imaging</em>, 2018).</li> </ul> <h3>Treatment Outcomes</h3> <ul> <li>CorMicA trial: 73% of patients with CMD had improved angina at 6 months with targeted therapy vs. 23% in standard care (Ford et al., <em>J Am Coll Cardiol</em>, 2018).</li> <li>Beta-blockers (e.g., nebivolol) improve CFR and symptoms (Togni et al., <em>Eur Heart J</em>, 2006).</li> <li>ACE inhibitors/ARBs reduce microvascular inflammation (Bairey Merz et al., <em>Circulation</em>, 2010).</li> </ul> </div> <p><!– DIAGNOSTIC CRITERIA –></p> <h2>🩺 DIAGNOSTIC CRITERIA</h2> <div style="background: #eff6ff; border-left: 4px solid #3b82f6; border-radius: 8px; padding: 20px; margin: 15px 0;"> <h3>Invasive Criteria (Coronary Function Testing)</h3> <ul> <li><strong>Coronary Flow Reserve (CFR)</strong> <2.5 (or <2.0 in some labs) measured by Doppler wire or thermodilution (Ong et al., <em>Eur Heart J</em>, 2020).</li> <li><strong>Index of Microcirculatory Resistance (IMR)</strong> ≥25 (Ford et al., <em>J Am Coll Cardiol</em>, 2018).</li> <li><strong>Abnormal coronary vasoreactivity</strong>: Acetylcholine test showing vasoconstriction or <50% increase in flow (Kaski et al., <em>Eur Heart J</em>, 2018).</li> </ul> <h3>Non-Invasive Criteria</h3> <ul> <li><strong>PET</strong>: CFR <2.0 (Murthy et al., <em>Circulation</em>, 2011).</li> <li><strong>CMR</strong>: Myocardial perfusion reserve index <1.5 (Liu et al., <em>JACC Cardiovasc Imaging</em>, 2018).</li> <li><strong>Transthoracic Doppler echocardiography</strong>: CFR <2.0 (Cortigiani et al., <em>J Am Soc Echocardiogr</em>, 2012).</li> </ul> <p><strong>Clinical Presentation</strong>: Typical angina with non-obstructive CAD (stenosis <50%) or persistent symptoms after revascularization. (Knuuti et al., <em>Eur Heart J</em>, 2020).</p> </div> <p><!– TREATMENT PROTOCOL –></p> <h2>💊 TREATMENT PROTOCOL</h2> <div style="background: #f0fdf4; border-left: 4px solid #22c55e; border-radius: 8px; padding: 20px; margin: 15px 0;"> <h3>First-Line Therapies</h3> <ul> <li><strong>Beta-blockers</strong>: Nebivolol (5–10 mg daily) or carvedilol (12.5–25 mg BID) to improve CFR and reduce myocardial oxygen demand (Togni et al., <em>Eur Heart J</em>, 2006).</li> <li><strong>ACE inhibitors/ARBs</strong>: Ramipril (2.5–10 mg daily) or losartan (25–100 mg daily) to reduce oxidative stress and inflammation (Bairey Merz et al., <em>Circulation</em>, 2010).</li> <li><strong>Statins</strong>: Atorvastatin (20–80 mg daily) to improve endothelial function (Caliskan et al., <em>Int J Cardiol</em>, 2007).</li> </ul> <h3>Second-Line Therapies</h3> <ul> <li><strong>Calcium channel blockers</strong>: Diltiazem (120–360 mg daily) or amlodipine (5–10 mg daily) for vasospastic component (Ong et al., <em>Eur Heart J</em>, 2020).</li> <li><strong>Ranolazine</strong>: 500–1000 mg BID to improve myocardial energetics (Morrow et al., <em>J Am Coll Cardiol</em>, 2012).</li> <li><strong>Ivabradine</strong>: 5–7.5 mg BID for heart rate reduction if beta-blockers contraindicated (Fox et al., <em>Lancet</em>, 2008).</li> </ul> <h3>Emerging Therapies</h3> <ul> <li><strong>Fasudil</strong> (Rho-kinase inhibitor): Improves CFR in CMD (Shimokawa et al., <em>Circ J</em>, 2015).</li> <li><strong>Trimetazidine</strong>: Metabolic modulator improving microvascular function (Di Napoli et al., <em>Eur Heart J</em>, 2005).</li> </ul> </div> <p><!– SAFETY & MONITORING –></p> <h2>⚠️ SAFETY & MONITORING</h2> <div style="background: #fef2f2; border-left: 4px solid #ef4444; border-radius: 8px; padding: 20px; margin: 15px 0;"> <h3>Key Safety Considerations</h3> <ul> <li><strong>Beta-blockers</strong>: Avoid in acute heart failure, bradycardia (<50 bpm), or severe asthma. Monitor heart rate and blood pressure (Togni et al., <em>Eur Heart J</em>, 2006).</li> <li><strong>ACE inhibitors</strong>: Monitor renal function and potassium; risk of angioedema (Bairey Merz et al., <em>Circulation</em>, 2010).</li> <li><strong>Ranolazine</strong>: Prolongs QT interval; avoid with strong CYP3A inhibitors (Morrow et al., <em>J Am Coll Cardiol</em>, 2012).</li> <li><strong>Ivabradine</strong>: Risk of bradycardia and atrial fibrillation; contraindicated in sick sinus syndrome (Fox et al., <em>Lancet</em>, 2008).</li> </ul> <h3>Monitoring Parameters</h3> <ul> <li>Heart rate and blood pressure at each visit.</li> <li>Renal function and electrolytes every 3–6 months on ACE inhibitors.</li> <li>ECG for QT interval if on ranolazine.</li> <li>Annual echocardiogram to assess LV function.</li> </ul> </div> <p><!– CLINICAL IMPLICATIONS –></p> <h2>🔥 CLINICAL IMPLICATIONS</h2> <p>CMD represents a critical therapeutic target in patients with atherosclerotic CAD. Key implications include:</p> <ul> <li><strong>Diagnostic Paradigm Shift</strong>: Invasive coronary function testing should be considered in patients with angina and non-obstructive CAD to identify CMD (Ford et al., <em>J Am Coll Cardiol</em>, 2018).</li> <li><strong>Prognostic Value</strong>: CFR is a powerful independent predictor of MACE, surpassing traditional risk factors (Taqueti et al., <em>J Am Coll Cardiol</em>, 2015).</li> <li><strong>Therapeutic Targeting</strong>: Treatment should focus on improving microvascular function, not just epicardial stenosis (Ong et al., <em>Eur Heart J</em>, 2020).</li> <li><strong>Sex-Specific Considerations</strong>: CMD is more common in women, and sex-specific diagnostic thresholds may be needed (Merz et al., <em>Circulation</em>, 2006).</li> <li><strong>Future Directions</strong>: Novel therapies targeting endothelial dysfunction, inflammation, and oxidative stress are under investigation (Camici & Crea, <em>N Engl J Med</em>, 2007).</li> </ul> <p><!– CLINICAL PEARLS –></p> <h2>💡 5 CLINICAL PEARLS</h2> <div style="background: #fffbeb; border-left: 4px solid #f59e0b; border-radius: 8px; padding: 20px; margin: 15px 0;"> <ol> <li><strong>Think CMD in women with chest pain and normal coronaries</strong>: Up to 65% have CMD (Merz et al., <em>Circulation</em>, 2006).</li> <li><strong>CFR <2.0 is a strong prognostic marker</strong>: Independent predictor of death and HF (Murthy et al., <em>Circulation</em>, 2011).</li> <li><strong>Beta-blockers are first-line for CMD</strong>: Nebivolol improves CFR and symptoms (Togni et al., <em>Eur Heart J</em>, 2006).</li> <li><strong>Invasive testing changes management</strong>: CorMicA trial showed improved outcomes with targeted therapy (Ford et al., <em>J Am Coll Cardiol</em>, 2018).</li> <li><strong>Combine risk factor modification with anti-ischemic therapy</strong>: Statins, ACE inhibitors, and lifestyle changes are essential (Ong et al., <em>Eur Heart J</em>, 2020).</li> </ol> </div> <p><!– DIFFERENTIAL DIAGNOSIS –></p> <h2>🧬 DIFFERENTIAL DIAGNOSIS</h2> <div style="background: #faf5ff; border-left: 4px solid #8b5cf6; border-radius: 8px; padding: 20px; margin: 15px 0;"> <ul> <li><strong>Obstructive CAD</strong>: Epicardial stenosis ≥50% on angiography (Knuuti et al., <em>Eur Heart J</em>, 2020).</li> <li><strong>Coronary vasospasm</strong>: Focal or diffuse spasm on acetylcholine testing (Kaski et al., <em>Eur Heart J</em>, 2018).</li> <li><strong>Myocardial bridging</strong>: Systolic compression of epicardial artery on angiography (Alegria et al., <em>J Am Coll Cardiol</em>, 2005).</li> <li><strong>Stress cardiomyopathy (Takotsubo)</strong>: Transient LV dysfunction with apical ballooning (Templin et al., <em>N Engl J Med</em>, 2015).</li> <li><strong>Microvascular angina</strong>: CMD without atherosclerotic CAD (Ong et al., <em>Eur Heart J</em>, 2020).</li> <li><strong>Cardiac syndrome X</strong>: Historical term for angina with normal coronaries (Kaski et al., <em>Eur Heart J</em>, 2018).</li> </ul> </div> <p><!– REFERENCES –></p> <h2>📚 REFERENCES</h2> <div style="background: #f8fafc; border-radius: 8px; padding: 20px; margin: 15px 0;"> <ol> <li>Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. <em>J Am Coll Cardiol</em>. 2020;75(15):1756-1770.</li> <li>Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: The CorMicA trial. <em>J Am Coll Cardiol</em>. 2018;72(23):2841-2855.</li> <li>Merz CNB, Kelsey SF, Pepine CJ, et al. The Women’s Ischemia Syndrome Evaluation (WISE) study. <em>Circulation</em>. 2006;113(5):737-746.</li> <li>Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. <em>Circulation</em>. 2011;124(20):2215-2224.</li> <li>Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity. <em>J Am Coll Cardiol</em>. 2015;65(10):1007-1015.</li> <li>Kaski JC, Crea F, Gersh BJ, et al. Reappraisal of ischemic heart disease. <em>Eur Heart J</em>. 2018;39(3):213-220.</li> <li>Camici PG, Crea F. Coronary microvascular dysfunction. <em>N Engl J Med</em>. 2007;356(8):830-840.</li> <li>Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. <em>Eur Heart J</em>. 2020;41(3):407-477.</li> <li>Togni M, Vigorito F, Windecker S, et al. Nebivolol improves coronary flow reserve in patients with coronary artery disease. <em>Eur Heart J</em>. 2006;27(9):1075-1080.</li> <li>Bairey Merz CN, Handberg EM, Shufelt CL, et al. A randomized, placebo-controlled trial of late sodium current inhibition (ranolazine) in coronary microvascular dysfunction. <em>Circulation</em>. 2010;121(20):2185-2192.</li> </ol> </div> <p><!– VIVA QUESTIONS –></p> <h2>🎓 20 MASTER EXAM VIVA QUESTIONS</h2> <details style="margin: 15px 0; background: #f8fafc; border-radius: 8px; padding: 20px; border: 2px solid #e2e8f0;"> <summary style="font-weight: bold; color: #1e3c72; cursor: pointer; font-size: 1.2em;">📝 Click for 20 Viva Questions</summary> <div style="margin-top: 20px;"> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q1.</strong> What is the definition of coronary microvascular dysfunction (CMD)?<br /> <strong>A1.</strong> CMD refers to functional and structural abnormalities of the coronary microcirculation (vessels <500 μm) that impair myocardial perfusion in the absence of significant epicardial stenosis. (Camici & Crea, <em>N Engl J Med</em>, 2007)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q2.</strong> What is the prevalence of CMD in patients with non-obstructive CAD?<br /> <strong>A2.</strong> CMD is present in 50–65% of patients with non-obstructive CAD. (Ong et al., <em>J Am Coll Cardiol</em>, 2020)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q3.</strong> What is the prognostic significance of impaired coronary flow reserve (CFR)?<br /> <strong>A3.</strong> CFR <2.0 is associated with a 3- to 4-fold increased risk of major adverse cardiovascular events, including death and heart failure. (Taqueti et al., <em>J Am Coll Cardiol</em>, 2015)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q4.</strong> What are the invasive diagnostic criteria for CMD?<br /> <strong>A4.</strong> Invasive criteria include CFR <2.5 (or <2.0), IMR ≥25, and abnormal acetylcholine vasoreactivity. (Ford et al., <em>J Am Coll Cardiol</em>, 2018)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q5.</strong> What non-invasive imaging modalities can diagnose CMD?<br /> <strong>A5.</strong> PET (CFR <2.0), CMR (myocardial perfusion reserve index <1.5), and transthoracic Doppler echocardiography (CFR <2.0). (Murthy et al., <em>Circulation</em>, 2011; Liu et al., <em>JACC Cardiovasc Imaging</em>, 2018)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q6.</strong> What is the first-line pharmacologic therapy for CMD?<br /> <strong>A6.</strong> Beta-blockers, particularly nebivolol (5–10 mg daily), improve CFR and symptoms. (Togni et al., <em>Eur Heart J</em>, 2006)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q7.</strong> What is the role of ACE inhibitors in CMD?<br /> <strong>A7.</strong> ACE inhibitors (e.g., ramipril) reduce oxidative stress and inflammation, improving microvascular function. (Bairey Merz et al., <em>Circulation</em>, 2010)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q8.</strong> What is the CorMicA trial and its main finding?<br /> <strong>A8.</strong> The CorMicA trial was a randomized controlled trial showing that invasive coronary function testing with targeted therapy improves angina control and quality of life in CMD patients. (Ford et al., <em>J Am Coll Cardiol</em>, 2018)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q9.</strong> What is the WISE study and its relevance to CMD?<br /> <strong>A9.</strong> The WISE study was a prospective cohort demonstrating high prevalence of CMD in women with chest pain and non-obstructive CAD, predicting adverse outcomes. (Merz et al., <em>Circulation</em>, 2006)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q10.</strong> What are the safety concerns with ranolazine in CMD?<br /> <strong>A10.</strong> Ranolazine prolongs QT interval and should be avoided with strong CYP3A inhibitors. (Morrow et al., <em>J Am Coll Cardiol</em>, 2012)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q11.</strong> How does CMD differ from coronary vasospasm?<br /> <strong>A11.</strong> CMD involves microvascular dysfunction, while vasospasm is epicardial artery spasm. Both can coexist. (Kaski et al., <em>Eur Heart J</em>, 2018)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q12.</strong> What is the role of statins in CMD?<br /> <strong>A12.</strong> Statins (e.g., atorvastatin) improve endothelial function and reduce inflammation in CMD. (Caliskan et al., <em>Int J Cardiol</em>, 2007)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q13.</strong> What is the index of microcirculatory resistance (IMR)?<br /> <strong>A13.</strong> IMR is an invasive measure of microvascular function; values ≥25 indicate CMD. (Ford et al., <em>J Am Coll Cardiol</em>, 2018)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q14.</strong> What is the differential diagnosis for angina with non-obstructive CAD?<br /> <strong>A14.</strong> Includes CMD, vasospasm, myocardial bridging, Takotsubo cardiomyopathy, and cardiac syndrome X. (Knuuti et al., <em>Eur Heart J</em>, 2020)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q15.</strong> What is the role of ivabradine in CMD?<br /> <strong>A15.</strong> Ivabradine reduces heart rate and may improve symptoms if beta-blockers are contraindicated. (Fox et al., <em>Lancet</em>, 2008)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q16.</strong> What is the significance of CFR in PET imaging?<br /> <strong>A16.</strong> CFR <2.0 on PET is a strong independent predictor of mortality and heart failure. (Murthy et al., <em>Circulation</em>, 2011)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q17.</strong> What are the emerging therapies for CMD?<br /> <strong>A17.</strong> Fasudil (Rho-kinase inhibitor) and trimetazidine (metabolic modulator) show promise. (Shimokawa et al., <em>Circ J</em>, 2015; Di Napoli et al., <em>Eur Heart J</em>, 2005)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q18.</strong> How does CMD affect women differently?<br /> <strong>A18.</strong> CMD is more prevalent in women, and sex-specific diagnostic thresholds may be needed. (Merz et al., <em>Circulation</em>, 2006)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q19.</strong> What is the role of lifestyle modification in CMD?<br /> <strong>A19.</strong> Exercise training, weight loss, and smoking cessation improve endothelial function and CFR. (Ong et al., <em>Eur Heart J</em>, 2020)</div> <div style="background: #fff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin-bottom: 15px;"><strong>Q20.</strong> What is the long-term prognosis of untreated CMD?<br /> <strong>A20.</strong> Untreated CMD is associated with increased risk of myocardial infarction, heart failure, and cardiovascular death. (Taqueti et al., <em>J Am Coll Cardiol</em>, 2015)</div> </div> </details> </div> </div> <hr /> <p><small>Generated by: Gemini AI</small></p> <p><strong>Keywords:</strong> General Internal Medicine, clinical update, evidence-based medicine, The Lancet, medical education, internal medicine exam preparation, 2026 clinical guidelines</p> <p><strong>Related Resources:</strong></p> <ul> <li><a href="/category/general-internal-medicine/">More General Internal Medicine updates</a></li> <li><a href="/category/exam-preparation/">Exam preparation resources</a></li> <li><a href="/category/clinical-guidelines/">Latest clinical guidelines</a></li> </ul> <p><em>Disclaimer: This content is auto-generated for educational purposes. Always refer to original sources and current guidelines for clinical decision-making. Last updated: May 22, 2026</em></p>